[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study] - Archive ouverte HAL Access content directly
Journal Articles Revue des Maladies Respiratoires Year : 2008

[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14)
1
2
3
4
5
6
7
8
9
10
11
12
13
14

Abstract

BACKGROUND: As chemotherapy gains wider acceptance for the treatment of earlier stages of NSCLC, particularly in the adjuvant and neoadjuvant setting, physicians face a growing population of high performance status patients who have relapsed after their first-line chemotherapy. The type of second-line chemotherapy after initial adjuvant or neoadjuvant treatment with a platinum-based regimen remains largely undefined. The current study has been designed to compare the classical mono chemotherapy docetaxel with a docetaxel cisplatin doublet. METHODS: Patients will be randomized in 2 arms. Arm: docetaxel cisplatin (cycles repeated every 21 days), 4 cycles followed by 2 cycles of docetaxel alone in case of objective response or stabilisation. Arm B: docetaxel alone (cycles repeated every 21 days), 4 cycles followed by 2 cycles of docetaxel alone in case of objective response or stabilisation. EXPECTED RESULTS: 300 patients will be randomized with a statistical hypothesis of a progression free survival of 3 months in the control arm and of 4.5 months in the experimental arm.
Not file

Dates and versions

inserm-00335220 , version 1 (28-10-2008)

Identifiers

  • HAL Id : inserm-00335220 , version 1
  • PUBMED : 18288059

Cite

Denis Moro-Sibilot, Fabrice Barlesi, Jean-François Timsit, Didier Debieuvre, Pierre Fournel, et al.. [How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]. Revue des Maladies Respiratoires, 2008, 25 (1), pp.91-6. ⟨inserm-00335220⟩
191 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More